Bibliography
0. Picture
1. Induction of Apoptosis in Human Leukemia Cells 
09 by Grape Seed Extract Occurs via 
Jan Activation of c-Jun NH2-Terminal Kinase (JNK)
Ning Gao,1,2 Amit Budhraja,2 Senping Cheng,2 Hua Yao,2 Zhuo Zhang,2 and Xianglin Shi2
1   Department of Pharmacognosy, School of Pharmacy, 3rd Military Medical University, 
    Chongqing, People’s Republic of China
2   Graduate Center for Toxicology, College of Medicine, University of Kentucky, Lexington, Kentucky
American Association for Cancer Research
Clinical Cancer Research http://www.aacr.org/home/scientists/publications-of-the-aacr.aspx
2009;15(1) January 1, 2009 http://clincancerres.aacrjournals.org/
2. Neurodegeneration:  Metallostasis and Proteostasis
11 Danilo Milardi and Enrico Rizzarelli (editors)
[Cambridge]: Royal Society of Chemistry, c2011
ISBN: 978-1-84973-301-4
Chapter 9 - The Role of Iron in Neurodegeneration
F. A. Zucca, F. A. Cupaioli and L. Zecca
3. Effects of oxidative stress on hematopoiesis of hematopoietic stem and
11 progenitor cells with iron overload.
Dec Article in Chinese
Xie F, Zhao MF, Zhu HB, Lu WY, Xu XN, Xiao X, Mu J, Liu PJ, Li Ym.
Department of Hematology & Oncology, Tianjin Medical University, Tianjin, China.
Shonghua Yi Xue Za Zhi, 2011 Dec 13;91(46):3284-8.
4. The effect of iron chelation on haematopoiesis in MDS patients
96 with transfusional iron overload.
Aug Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT,
Christensen T, Boesen AM, Ellegaard J.
Department of Medicine and Haematology, Aarhus University Hospital, Denmark.
British Journal of Haematology, 94(2):288-99
5. Treatment of transfusional iron overload (TIO) in patients with
08 myelodysplastic syndrome (MDS).
May A. Raptis, M. S. Duh, J. R. Weiner, S. Wang, B. Fortner, N. Mody-Patel, J. Scott
American Society of Clinical Oncology
Journal of Clinical Oncology 26: 2008 (May 20 suppl; abstr 7098)
6. Review  PRACTICAL MANAGEMENT OF IRON OVERLOAD
01 Professor John B. Porter
University College London
British Journal of Haematology, 2001, 115, 239-252
© 2001 Blackwell Science Ltd
7. Management of transfusional iron overload --
11 differential properties and efficacy of iron chelating agents
Janet L Kwiatkowski
The Children's Hospital of Philadelphia
Division of Hematology and
University of Pennsylvania School of Medicine
Journal of Blood Medicine 2011:2 135-149
© 2011 Kwiakowski, publisher and licensee Dove Medical Press Ltd.
8. Actinide Interactions with Microbial Chelators:  How
00 Desferrioxamine Siderophores Affect Plutonium Chemistry and
Facilitate Microbial Uptake
Mary Neu
Chemistry Division
Los Alamos National Laboratory
Reprinted from Los Alamos Science, no. 26, 2000
9. PRESCRIPTION DRUG PRODUCT LIST
11 and
PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST
FDA Orange Book
10. HIGHLIGHTS OF PRESCRIBING INFORMATION
11 EXJADE®
FDA
Reference ID: 2998576
11. Important Information about Exjade® (deferasirox)
10 IMPORTANT DRUG WARNING
Feb NOVARTIS ONCOLOGY
12. New Drug Application 21-825
11 Ferriprox® (deferiprone)
Sep FDA Briefing Document for
The Oncologic Drugs Advisory Committee
13. US FDA
05 CENTER FOR BIOLOGICS EVALUATION AND RESEARCH
Sep BLOOD PRODUCTS ADVISORY COMMITTEE
Center for Drug Evaluation & Research
CDER Advisory Committee
Conference Room, Rm. 1066
Topic I:  NDA  21-882
ICL670  aka  deferasirox  brand name  Exjade